Another busy morning ahead of a well-deserved weekend! We had negative news overnight after the WHO published a draft paper suggesting that Gilead’s covid-19 drug (remdesivir) study failed. Our Pharma analyst has suggested that we should wait though as bigger studies are still underway. Elsewhere, the latest US Aid Package got through the White House overnight and is subject to Mr. Trump’s approval today. Apparently another package is on its way so let’s see if we hear anything else on that front this afternoon. Here in Europe, leaders managed to come up with an agreement in the short-term (worth €540 billion) but failed to agree on a long-term plan.
The content on this site is available to all Redburn clients as part of Redburn Execution’s standard service. It is not considered substantive research and there are no commercial implications to viewing these pages.
Please enter your email address below to view this page. If you are still unable to access the page, please speak to your account manager.